mimedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. the company processes the human placental tissue utilizing its proprietary purion® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. mimedx has supplied more than two million allografts, through both direct and consignment shipments. for additional information, please visit www.mimedx.com.
Company profile
Ticker
MDXG
Exchange
Website
CEO
Timothy R. Wright
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Alynx, Co.
SEC CIK
Corporate docs
Subsidiaries
MiMedx Tissue Services, LLC • MiMedx Processing Services, LLC • MiMedx Supply, LLC ...
IRS number
900300868
MDXG stock data
Latest filings (excl ownership)
8-K
MIMEDX Announces First Quarter 2024 Operating and Financial
30 Apr 24
10-Q
2024 Q1
Quarterly report
30 Apr 24
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
8-K
MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA
27 Mar 24
8-K
MIMEDX Announces Appointment of Two New Independent Directors
4 Mar 24
8-K
MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
MIMEDX Announces Improved Capital Structure with New Senior
22 Jan 24
8-K
MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock
28 Dec 23
Transcripts
MDXG
Earnings call transcript
2024 Q1
30 Apr 24
MDXG
Earnings call transcript
2023 Q4
28 Feb 24
MDXG
Earnings call transcript
2023 Q3
30 Oct 23
MDXG
Earnings call transcript
2023 Q2
1 Aug 23
MDXG
Earnings call transcript
2023 Q1
2 May 23
MDXG
Earnings call transcript
2022 Q4
28 Feb 23
MDXG
Earnings call transcript
2022 Q3
2 Nov 22
MDXG
Earnings call transcript
2022 Q2
3 Aug 22
MDXG
Earnings call transcript
2022 Q1
4 May 22
MDXG
Earnings call transcript
2021 Q4
1 Mar 22
Latest ownership filings
4
William Frank IV Hulse
9 May 24
4
William Frank IV Hulse
24 Apr 24
4
William Frank IV Hulse
10 Apr 24
3
DOROTHY E PUHY
18 Mar 24
3
Tiffany Olson
18 Mar 24
4
William Frank IV Hulse
15 Mar 24
4
William Frank IV Hulse
5 Mar 24
4
Ricci S Whitlow
5 Mar 24
4
RICE DOUG
5 Mar 24
4
Ricci S Whitlow
21 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
48.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 148 |
Opened positions | 27 |
Closed positions | 64 |
Increased positions | 35 |
Reduced positions | 49 |
13F shares | Current |
---|---|
Total value | 290.35 bn |
Total shares | 71.94 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Falcon Fund 2 Holding | 28.20 mm | $250.94 mm |
Prescience Investment | 7.60 mm | $0.00 |
Vanguard | 6.57 mm | $57.59 bn |
STT State Street | 4.09 mm | $35.86 bn |
Paradigm Capital Management | 3.43 mm | $30.08 bn |
MS Morgan Stanley | 1.59 mm | $13.92 bn |
Richmond Brothers | 1.40 mm | $12.32 bn |
Renaissance Technologies | 1.25 mm | $10.98 mm |
Charles Schwab Investment Management | 1.13 mm | $9.95 bn |
NTRS Northern Trust | 1.08 mm | $9.44 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 May 24 | William Frank IV Hulse | Common Stock | Payment of exercise | Dispose F | No | No | 7.2 | 8,896 | 64.05 k | 453,271 |
23 Apr 24 | William Frank IV Hulse | Common Stock | Payment of exercise | Dispose F | No | No | 6.51 | 8,896 | 57.91 k | 462,167 |
8 Apr 24 | William Frank IV Hulse | Common Stock | Payment of exercise | Dispose F | No | No | 6.9 | 8,896 | 61.38 k | 471,063 |
13 Mar 24 | William Frank IV Hulse | Common Stock | Sell | Dispose S | No | No | 7.95 | 20,381 | 162.03 k | 479,959 |
4 Mar 24 | William Frank IV Hulse | Common Stock | Payment of exercise | Dispose F | No | No | 8.26 | 15,351 | 126.80 k | 500,340 |
1 Mar 24 | William Frank IV Hulse | Common Stock | Grant | Acquire A | No | No | 0 | 59,127 | 0.00 | 515,691 |
1 Mar 24 | William Frank IV Hulse | Stock Options Common Stock | Grant | Acquire A | No | No | 8.63 | 71,541 | 617.40 k | 71,541 |
News
HC Wainwright & Co. Reiterates Buy on MiMedx Group, Maintains $11 Price Target
1 May 24
MiMedx Group Q1 2024 Adj EPS $0.07 Beats $0.04 Estimate, Sales $84.709M Beat $79.361M Estimate
30 Apr 24
Lake Street Initiates Coverage On MiMedx Group with Buy Rating, Announces Price Target of $12
7 Mar 24
Mizuho Maintains Buy Rating for MiMedx Group: Here's What You Need To Know
1 Mar 24
Mizuho Maintains Buy on MiMedx Group, Raises Price Target to $14
1 Mar 24